A Phase 2 interventional study of Aspirin + Clopidogrel and Aspirin in Acute Ischemic Stroke, sponsored by University of Alberta. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by University of Alberta · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing aspirin in Ischemic Stroke — 7 open to participants now, 7 under way, 2 of them phase 3. Aspirin · Ischemic Stroke.
Among the 23 studies testing aspirin in Ischemic Stroke, this one is the 13th largest by planned enrollment, is the only one that started in 2027, is one of 3 in phase 2, and was the 22nd registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →7 of the 23 studies testing aspirin in Ischemic Stroke are open now, in 5 countries. Recruiting first, the newest first:
Capital Medical University · Sites in China
Ages 18+
Rajaie Cardiovascular Medical and Research Center · Sites in Iran, Islamic Republic of
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Azienda Usl di Bologna · Sites in Italy
Ages 18+
Sichuan Provincial People's Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 400 across the 23 interventional studies. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 23 have an industry lead sponsor. The 10 most frequent:
University of Alberta is the lead sponsor of 825 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
11 studies in Ischemic Stroke by University of Alberta: 2 open now, 3 under way, none of them phase 3. Of 7 finished, 1 (14%) have results posted.
Among the 11 studies in Ischemic Stroke by University of Alberta, this one is the only one that started in 2027, is one of 3 in phase 2, and was the 11th registered.
University of Alberta’s Ischemic Stroke studies by the year they started, since 2009.
2 of the studies testing aspirin in Ischemic Stroke that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT05910125Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing aspirin in Ischemic Stroke, from their registry updates:
Among University of Alberta’s 11 in Ischemic Stroke:
This tab as a report to print or save as PDF → With an account.
Strokes are an major cause of disability. The most common stroke is called an "ischemic stroke". These strokes happen when a blood vessel in the brain is blocked by a clot. The blockage decreases blood flow. This damages the brain. To treat stroke, doctors use medicines and procedures to remove the clot.
After patients have a stroke, they may have another one in the first few weeks. Doctors often use aspirin to prevent another stroke. However, more strokes might be prevented if we use aspirin together with a medicine called clopidogrel or with ticagrelor. Aspirin plus clopidogrel or aspirin plus ticagrelor might prevent more clots from forming in the blood. The risk of these medicines are bleeding.
This study will test if using aspirin plus clopidogrel or aspirin plus ticagrelor together for 3 weeks is safe and practical when compared to aspirin alone. Patients will have a chance to join the study soon after they have been treated for a stroke. They will be checked for a low risk of bleeding with a brain scan. The study treatment will be chosen by chance like a coin toss. One third will take aspirin alone. One third will take aspirin and clopidogrel. One a third will take aspirin and ticagrelor. The study team will follow participants for three months.
Purpose - The purpose of this study is to assess the safety and efficacy of two different dual antiplatelet treatments (DAPT) versus aspirin alone in patients who have received treatment for acute ischemic stroke.
Hypothesis - We hypothesize that it is safe and feasable to combine a second antiplatelet medication (either ticegrelor or clopidogrel) with standard-of-care for 21 days in patients with acute ischemic stroke with mild to moderate neurological deficits following reperfusion therapy, when initiated within 30 hours of intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT).
Justification - Patients who have had an ischemic stroke are at higher risk of having another ischemic stroke. This risk is highest in the first 21 days after a stroke and varies depending on the treatment received.
Currently, doctors give patients the medication aspirin every day, starting 24 hours after stroke treatment, to prevent recurrent stroke. However, some studies have shown that giving another medication, clopidogrel, in addition to aspirin is safe and may work better than aspirin alone at preventing repeat strokes. The combination of aspirin with a medication known as ticagrelor has also been associated with a relative risk reduction for recurrent stroke. Aspirin, clopidogrel, and ticagrelor are a type of medication called an antiplatelet, they work by decreasing clots from forming in the blood. When medications are given together it is called dual antiplatelet treatment (DAPT). The main risk of antiplatelet medications is bleeding.
DAPT is currently used as a standard treatment for patients with transient ischemic attack (TIA) or minor ischemic stroke in whom more aggressive treatment such as thrombolysis or EVT are not appropriate. However it is not known whether DAPT is safe and effective at preventing recurrent ischemic stroke in patients who have received thrombolysis and/or EVT.
Objectives - The primary outcome of this study is to assess feasibility. This will be assessed by the recruitment rate which will be estimated based on the average number of patients recruited per center over 12 months. Other secondary feasibility outcomes will include medication adherence (defined as a yes or a no to the ability to take all the doses of the antiplatelet therapy for 21 days), retention rates (defined as the proportion of participants that complete the 30-day follow-up), and gene (CYP2C19) carrier assessment workflow time. The gene carrier assessment workflow will be assessed in two parts; the time it takes to obtain results from time of randomization as well as the barriers of testing.
Safety will be measured as a secondary outcome. This outcome will be measured based on the proportion of patients with symptomatic intracranial hemorrhage (SICH). This will be defined as worsening of NIHSS ≥4 compared to score at randomization and systemic bleeding associated with a decrease in hemoglobin by 20 g/L.
Secondary clinical outcomes include the proportion of patients with worsening focal neurologic deficit defined as an increase in NIHSS score by ≥4, as well as the proportion of patients with recurrent stroke, deep vein thrombosis, pulmonary embolism, acute coronary syndromes, prevalence of CYP2C19 mutation, atrial fibrillation, and death.
Research Method/Procedures - Patients who have received treatment for an ischemic stroke will first be screened to rule out patients at high risk of bleeding according to the exclusion criteria. Following informed consent, patients at low risk of bleeding will be enrolled into the study within 30 hours after their initial stroke treatment. Enrolled patients will be randomly assigned to the clopidogrel plus aspirin group (300 mg loading dose of clopidogrel plus 160 mg aspirin on day 1; followed by clopidogrel 75 mg plus aspirin 81 mg daily from day 2 - day 21, followed by aspirin 81 mg to be continued if no alternate treatment is indicated), ticagrelor plus aspirin group (On day 1 participants will receive a loading dose of 180mg of ticagrelor plus a 160mg aspirin; followed by 90 mg of ticagrelor twice daily plus aspirin 81 mg from day 2 - day 21), or aspirin alone group (aspirin 81 mg daily). All patients will receive guideline-based stroke care for vascular risk factor control and hospital management.
Inclusion criteria
Exclusion criteria
Participant follow up visits:
Day 1 and Day 7/Discharge: The study team member will visit the patient and complete a National Institute of Health Stroke Scale (NIHSS) assessment (uploaded to document section) and screen the patient for adverse events. Follow up imaging and vital signs will be done as per standard of care and collected by the study team from the electronic medical records system. Concomitant medications, study drug compliance, and adverse events will be recorded from the electronic medical records system. At time of randomization the study team will also collect buccal swap samples and complete the CYP2C19 gene test.
Day 30±6: A study team member will call patients (or visit if patient is admitted to hospital) to complete a Modified Rankin Scale assessment (mRS), EQ-5D-5L assessment, screen the patient for adverse events, and assess concomitant and study drug medication usage.
Day 90±15: Whenever possible, patients will be seen in person at the Stroke Prevention Clinic. A study team member will complete a Modified Rankin Scale assessment (mRS), EQ-5D-5L assessment, and screen the patient for adverse events. Vital signs and neuro imaging (CT or MRI scan) will be done as per standard of care and collected from the electronic medical records system.
Plan for Data Analysis - We will enrol 300 patients at a 1:1:1 ratio. 100 patients will be enrolled in the clopidogrel plus aspirin group, 100 patients will be enrolled in the ticagrelor plus aspirin group, and 100 patients will be enrolled in the aspirin-alone group. In patients with moderate (10 ≤ NIHSS) ischemic stroke dual antiplatelet is associated with a 0.1-0.9% risk of intracranial hemorrhage thus a reliable sample would be 100 in each group.
The criteria were revised on the registry on Nov 13, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Aspirin
Drug: Aspirin + Clopidogrel
Drug: Aspirin + Ticagrelor
Drug pages: AspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ClopidogrelStudies of ClopidogrelClopidogrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Enrolled patients with acute ischemic stroke will be randomly assigned to the clopidogrel plus aspirin group (300 mg loading dose of clopidogrel plus 160 mg aspirin on day 1; followed by clopidogrel 75 mg plus aspirin 81 mg daily from day 2-day 21, followed by aspirin 81 mg to be continued if no alternate treatment is indicated).
Also known as: Dual antiplatelet treatment
Aspirin 81 mg once daily alone
Drug pages: AspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TicagrelorStudies of TicagrelorTicagrelor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Enrolled patients with acute ischemic stroke will be randomly assigned to the ticagrelor plus aspirin group (a loading dose 180mg of ticagrelor plus a 160mg aspirin; followed by 90 mg of ticagrelor twice daily plus aspirin 81 mg from day 2 - day 21, followed by aspirin 81 mg to be continued if no alternate treatment is indicated).
Safety
Safety will be assessed as a proportion of patients with symptomatic hemorrhagic transformation, defined as worsening of NIHSS ≥4 compared to NIHSS at the time of randomization and hemorrhage is attributable to the antiplatelet therapy by the treatment team.
Time frame: 90 days
Feasibility
Feasibility will be assessed as a proportion of recruited patients complete the study intervention for 21 days.
Time frame: 21 days
Early Neurological Deterioration
Secondary outcome measures include the proportion of patients with worsening focal neurologic deficit by NIHSS ≥4 at day seven or discharge not due to hemorrhagic transformation or any intracranial hemorrhage. Worsening will be defined as a change in NIHSS compared to NIHSS at the time of randomization.
Time frame: 7 days
Recurrent Stroke
Time frame: 90 days
Death
Time frame: 90 days
Non-Stroke Thrombotic events
Time frame: 90 days
Plan to share: Yes — IPD will be available to investigators in consultation with the principal investigators
Supporting information: Study protocol, Informed consent form
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2030, 47 months later.
Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 47 months is above that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Sep 2025 → Jan 2027, primary completion Jul 2026 → Dec 2030 and completion Jul 2026 → Dec 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aspirin · Clopidogrel · Ticagrelor